Federal Court of Appeal Decisions

Decision Information

Decision Content

Federal Court of Appeal

 

Cour d'appel fédérale


Date: 20110117

Docket: A-444-10

Citation: 2011 FCA 16

 

CORAM:       SHARLOW J.A.

                        DAWSON J.A.

                        LAYDEN-STEVENSON J.A.

 

BETWEEN:

 

JANSSEN INC. AND

JANSSEN PHARMACEUTICA N.V.

Appellants

 

and

 

MYLAN PHARMACEUTICALS ULC AND

THE MINISTER OF HEALTH

Respondents

 

 

 

 

Heard at Toronto, Ontario, on January 17, 2011.

Judgment delivered from the Bench at Toronto, Ontario, on January 17, 2011.

 

REASONS FOR JUDGMENT OF THE COURT BY:                                             SHARLOW J.A.


Federal Court of Appeal

 

Cour d'appel fédérale


Date: 20110117

Docket: A-444-10

Citation: 2011 FCA 16

 

CORAM:       SHARLOW J.A.

                        DAWSON J.A.

                        LAYDEN-STEVENSON J.A.

 

BETWEEN:

JANSSEN INC. AND

JANSSEN PHARMACEUTICA N.V.

Appellants

 

and

 

MYLAN PHARMACEUTICALS ULC AND

THE MINISTER OF HEALTH

Respondents

 

 

REASONS FOR JUDGMENT OF THE COURT

(Delivered from the Bench at Toronto, Ontario, on January 17, 2011)

SHARLOW J.A.

[1]               It is well established that an appeal from a judgment dismissing an application under the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 becomes moot once the notice of compliance is issued because it is no longer possible for the Court to prohibit the Minister from issuing the notice of compliance. That is clearly the case here. Therefore, the only issue is whether, based on Borowski v. Canada (Attorney General), [1989] 1 S.C.R. 342, and other relevant jurisprudence, this Court should hear the appeal despite its mootness.

 

[2]               Despite the compelling and able submissions of Mr. Markwell, we are not persuaded that this moot appeal should be heard. We see nothing to distinguish this case from the many cases in which this Court has declined to hear a moot appeal in a proceeding under the NOC Regulations. We are all of the view that the question of patent law raised in this case is best determined in the context of an action for infringement of the patent in issue.

 

[3]               For that reason, the motion to dismiss the appeal for mootness will be granted with costs.

 

 

"K. Sharlow"

J.A.


FEDERAL COURT OF APPEAL

 

NAMES OF COUNSEL AND SOLICITORS OF RECORD

 

 

DOCKET:                                                                              A-444-10

 

(APPEAL FROM AN ORDER OF THE HONOURABLE JUSTICE BARNES DATED NOVEMBER 10, 2010, DOCKET NO. T-175-09)

 

STYLE OF CAUSE:                                                              JANSSEN PHARMACEUTICA N.V. v. MYLAN PHARMACEUTICALS ULC AND THE MINISTER OF HEALTH

 

PLACE OF HEARING:                                                        Toronto, Ontario

 

DATE OF HEARING:                                                          January 17, 2011

 

REASONS FOR JUDGMENT

OF THE COURT BY:                                                           SHARLOW J.A.

                                                                                                DAWSON J.A.

                                                                                                LAYDEN-STEVENSON J.A.

 

DELIVERED FROM THE BENCH BY:                            SHARLOW J.A.

 

 

APPEARANCES:

 

Jason Markwell

Amy E. Grenon

FOR THE APPELLANTS

 

 

Tim Gilbert

Nathaniel Lipkus

FOR THE RESPONDENTS

 

 

SOLICITORS OF RECORD:

 

Ogilvy Renaud LLP

Toronto, Ontario

FOR THE APPELLANTS

 

 

Gilbert’s LLP

Toronto, Ontario

FOR THE RESPONDENTS

 

 

 

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.